QUEBEC, Oct. 2, 2013 /CNW Telbec/ - Today and tomorrow, the main stakeholders of the pharmaceutical and biopharmaceutical industry, venture capital companies, academic researchers and government representative will be brought together for the 19th edition of BioContact Quebec. During two days, they will have the opportunity to develop new partnerships. "This is an exceptional opportunity for the pharmaceutical and biopharmaceutical industry, which has been experiencing major changes in the recent years", explained Dr. Martin Godbout, president of the event.
20 selected biopharmaceutical societies will present their most recent discoveries. As well, the 2013 edition will feature 8 plenary sessions under such themes as:
- Funding and new emerging virtual business models;
- Partnership: A tool box for the biopharmaceutical sector;
- Medical devices and information technology (IT) in health services;
- Merging and acquisition strategies;
- Patenting strategies;
- Orphan drugs and rare genetic diseases.
Not to be missed today
The opening conference (12:30 p.m.) Mr. Gary King, Executive Vice-President, International Operations, Myriad Genetics & Laboratories, will be speaking on the new genetic tests and companion diagnostics used in the development of new therapeutic treatment.
The Knock-out event (at 3:30 p.m.) Amorchem's Knock-out™ event will allow five academic researchers to present their research project, offering new innovating medical applications, to a panel of veterans from the biopharmaceutical industry. They will select the grand winner who will receive funding for his research project in the amount of $500,000. A first in Quebec!
Media accreditation required
To participate in the 19th edition of BioContact Québec in the quality of MEDIA, journalists must request an accreditation. They must contact the pressroom co-ordinator.
SOURCE: BIOCONTACT QUEBEC
For further information:
Hélène Turcotte, Press-room Coordinator
BioContact Québec 2013